Standout Papers

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group 2012 2026 2016 2021 1.1k
  1. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012)
    Keith T. Flaherty, Caroline Robert et al. Zurich Open Repository and Archive (University of Zurich)
  2. Metastatic disease from uveal melanoma: treatment options and future prospects (2016)
    Richard D. Carvajal, Gary K. Schwartz et al. British Journal of Ophthalmology

Immediate Impact

6 by Nobel laureates 22 from Science/Nature 68 standout
Sub-graph 1 of 21

Citing Papers

Metabolic reprogramming in cancer: Mechanisms and therapeutics
2023 Standout
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
2023 Standout
12 intermediate papers

Works of Paul Nathan being referenced

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
2018
Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.
2018
and 8 more

Author Peers

Author Last Decade Papers Cites
Paul Nathan 3554 3730 1940 267 7.7k
Nicolás André 4010 2732 1180 259 8.4k
Yutaka Takahashi 3041 1987 1609 295 7.9k
Gene P. Siegal 5247 4337 2883 326 12.3k
Stefania Staibano 2713 2339 1154 228 6.3k
Steven J. Harper 4488 1215 748 141 8.1k
Alessandro Testori 3523 5922 862 212 9.3k
Xiaohong Wang 5042 1321 999 265 8.8k
Michael Neumaier 2184 1631 620 215 6.4k
Peter A. McCue 5157 3253 2067 180 11.1k
Johannes Wolff 2864 1338 1191 229 7.4k

All Works

Loading papers...

Rankless by CCL
2026